Amneal Pharmaceuticals (NYSE:AMRX – Free Report) had its price objective upped by Piper Sandler from $3.00 to $5.00 in a report published on Monday morning, Marketbeat.com reports. They currently have an overweight rating on the stock. Other equities analysts have also recently issued reports about the company. 500.com reissued a maintains rating on shares of […]